Compare AWX & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AWX | LEXX |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3M | 8.7M |
| IPO Year | 1998 | 2011 |
| Metric | AWX | LEXX |
|---|---|---|
| Price | $2.70 | $8.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 21.5K | ★ 106.4K |
| Earning Date | 05-11-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,090,000.00 | $705,923.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $601.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 3.14 | ★ 52.05 |
| 52 Week Low | $2.40 | $0.35 |
| 52 Week High | $5.43 | $8.26 |
| Indicator | AWX | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 53.65 | 93.61 |
| Support Level | $2.51 | $0.65 |
| Resistance Level | $2.81 | N/A |
| Average True Range (ATR) | 0.11 | 0.66 |
| MACD | 0.02 | 0.56 |
| Stochastic Oscillator | 47.34 | 98.93 |
Avalon Holdings Corp is a waste management company. The company provides waste management services to industrial, commercial, municipal, and governmental customers in selected northeastern and midwestern U.S. markets. The company has two operating segments. The Waste management services segment which is the key revenue driver, includes waste disposal services, captive landfill operations, and saltwater injection well operations. Its Golf and related operations segment includes management of golf courses and related clubhouses, a hotel, fitness centers, tennis courts, salon and spa services, dining, banquet, and conference facilities.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.